SkyePharma to Present at the Deutsche Bank European Healthcare, Specialty Pharma and Biotech Conference LONDON, June 10 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE: Nasdaq:LSE:SKYE) announces today that the Company's Chief Executive Officer, Michael Ashton, will make a presentation at the Deutsche Bank European Healthcare, Specialty Pharma and Biotech Conference on Thursday, June 17th, 2004 at 09:15 a.m. (BST) in London. The presentation will not be webcast but will be recorded by video and a PDF of the presentation will be posted on the conference website at the end of the meeting. For the slides of this presentation, please visit SkyePharma's website http://www.skyepharma.com/ under Investor Relations / Presentations. About SkyePharma SkyePharma develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now ten approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit http://www.skyepharma.com/ . For further information please contact: SkyePharma PLC +44 207 491 1777 Michael Ashton, Chief Executive Officer Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court DATASOURCE: SkyePharma PLC CONTACT: Michael Ashton, Chief Executive Officer, Peter Laing, Director of Corporate Communications, +44-207-491-5124, or Sandra Haughton, US Investor Relations, +1-212-753-5780, all of SkyePharma PLC, +44-207-491-1777; or Tim Anderson, or Mark Court, both of Buchanan Communications, +44-207-466-5000, for SkyePharma PLC Web site: http://www.skyepharma.com/

Copyright